SCOT-HEART试验中稳定性胸痛患者的辐射暴露评估
该研究为SCOT-HEART试验的二次分析,纳入6个招募中心和2个影像中心的2894例稳定性胸痛患者,评估5年累积辐射剂量。冠状动脉CTA组5年累积有效剂量中位数8.1 mSv,高于标准治疗组的0 mSv(P < .001);在接受任何影像检查的参与者中,CTA组为8.6 mSv,仍高于标准治疗组的6.4 mSv(P < .001)。
要点
- 冠状动脉钙化评分中位有效剂量3.0 mSv,冠状动脉CTA为4.1 mSv,SPECT为7.4 mSv,有创冠状动脉造影为4.1 mSv。
- 5年累积剂量CTA组中位8.1 mSv vs 标准治疗组0 mSv,差异有统计学意义(P < .001)。
- 接受任何影像检查者中,CTA组累积剂量中位8.6 mSv vs 标准治疗组6.4 mSv(P < .001)。
核心结论
- 在SCOT-HEART试验中,冠状动脉CTA组5年累积辐射剂量高于标准治疗组,主要归因于CT检查的辐射暴露。
研究设计与样本
- SCOT-HEART试验的二次分析,纳入6个招募中心和2个影像中心,参与者于2010年11月18日至2014年9月24日招募,随访至2018年1月31日,随机分为标准治疗加CT组(n = 1466)和单纯标准治疗组(n = 1428)。
诊断标准与关键数值
- 冠状动脉钙化评分中位有效剂量3.0 mSv(IQR 2.6-3.3 mSv)。
- 冠状动脉CTA中位有效剂量4.1 mSv(IQR 2.6-6.1 mSv)。
- SPECT中位有效剂量7.4 mSv(IQR 6.2-8.5 mSv)。
- 有创冠状动脉造影中位有效剂量4.1 mSv(IQR 2.5-6.8 mSv)。
- 心脏CT有效剂量转换系数为0.026 mSv/mGy·cm。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background In the Scottish Computed Tomography of the Heart (SCOT-HEART) trial in individuals with stable chest pain, a treatment strategy based on coronary CT angiography (CTA) led to improved outcomes. Purpose To assess 5-year cumulative radiation doses of participants undergoing investigation for suspected angina due to coronary artery disease with or without coronary CTA. Materials and Methods This secondary analysis of the SCOT-HEART trial included data from six of 12 recruiting sites and two of three imaging sites. Participants were recruited between November 18, 2010, and September 24, 2014, with follow-up through January 31, 2018. Study participants had been randomized (at a one-to-one ratio) to standard care with CT (n = 1466) or standard care alone (n = 1428). Imaging was performed on a 64-detector (n = 223) or 320-detector row scanner (n = 1466). Radiation dose from CT (dose-length product), SPECT (injected activity), and invasive coronary angiography (ICA; kerma-area product) was assessed for 5 years after enrollment. Effective dose was calculated using conversion factors appropriate for the imaging modality and body region imaged (using 0.026 mSv/mGy · cm for cardiac CT). Results Cumulative radiation dose was assessed in 2894 participants. Median effective dose was 3.0 mSv (IQR, 2.6-3.3 mSv) for coronary calcium scoring, 4.1 mSv (IQR, 2.6-6.1 mSv) for coronary CTA, 7.4 mSv (IQR, 6.2-8.5 mSv) for SPECT, and 4.1 mSv (IQR, 2.5-6.8 mSv) for ICA. After 5 years, total per-participant cumulative dose was higher in the CT group (median, 8.1 mSv; IQR, 5.5-12.4 mSv) compared with standard-care group (median, 0 mSv; IQR, 0-4.5 mSv; P < .001). In participants who underwent any imaging, cumulative radiation exposure was higher in the CT group (n = 1345; median, 8.6 mSv; IQR, 6.1-13.3 mSv) compared with standard-care group (n = 549; median, 6.4 mSv; IQR, 3.4-9.2 mSv; P < .001). Conclusion In the SCOT-HEART trial, the 5-year cumulative radiation dose from cardiac imaging was higher in the coronary CT angiography group compared with the standard-care group, largely because of the radiation exposure from CT. Clinical trial registration no. NCT01149590 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Dodd and Bosserdt in this issue.
引用
- Chiong J, Ramkumar PG, Weir NW, et al. Evaluating Radiation Exposure in Patients with Stable Chest Pain in the SCOT-HEART Trial. Radiology. 2023. PMID: 37526539. doi:10.1148/radiol.221963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。